vs
Apellis Pharmaceuticals, Inc.（APLS）与INTERNATIONAL BANCSHARES CORP（IBOC）财务数据对比。点击上方公司名可切换其他公司
INTERNATIONAL BANCSHARES CORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$217.7M vs $199.9M），INTERNATIONAL BANCSHARES CORP净利率更高（62.3% vs -29.5%，领先91.8%），INTERNATIONAL BANCSHARES CORP同比增速更快（4.5% vs -5.9%），INTERNATIONAL BANCSHARES CORP自由现金流更多（$472.9M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 2.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
国际银行股份公司（International Bancshares Corporation）是总部位于美国得克萨斯州拉雷多的银行控股公司，核心子公司为国际商业银行。目前集团通过旗下银行子公司运营217个营业网点、315台自动柜员机，服务覆盖得克萨斯州、俄克拉荷马州的88个城镇社区。
APLS vs IBOC — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $217.7M |
| 净利润 | $-59.0M | $106.9M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 62.8% |
| 净利率 | -29.5% | 62.3% |
| 营收同比 | -5.9% | 4.5% |
| 净利润同比 | -62.2% | -7.1% |
| 每股收益（稀释后） | $-0.40 | $1.71 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $217.7M | ||
| Q3 25 | $458.6M | $218.1M | ||
| Q2 25 | $178.5M | $208.2M | ||
| Q1 25 | $166.8M | $198.2M | ||
| Q4 24 | $212.5M | $208.3M | ||
| Q3 24 | $196.8M | $211.8M | ||
| Q2 24 | $199.7M | $207.8M | ||
| Q1 24 | $172.3M | $205.8M |
| Q4 25 | $-59.0M | $106.9M | ||
| Q3 25 | $215.7M | $108.4M | ||
| Q2 25 | $-42.2M | $100.1M | ||
| Q1 25 | $-92.2M | $96.9M | ||
| Q4 24 | $-36.4M | $115.1M | ||
| Q3 24 | $-57.4M | $99.8M | ||
| Q2 24 | $-37.7M | $97.0M | ||
| Q1 24 | $-66.4M | $97.3M |
| Q4 25 | -25.6% | 62.8% | ||
| Q3 25 | 48.7% | 62.6% | ||
| Q2 25 | -18.6% | 60.5% | ||
| Q1 25 | -50.0% | 61.1% | ||
| Q4 24 | -12.3% | 64.2% | ||
| Q3 24 | -24.0% | 60.0% | ||
| Q2 24 | -14.7% | 60.1% | ||
| Q1 24 | -36.0% | 59.9% |
| Q4 25 | -29.5% | 62.3% | ||
| Q3 25 | 47.0% | 49.7% | ||
| Q2 25 | -23.6% | 48.1% | ||
| Q1 25 | -55.3% | 48.9% | ||
| Q4 24 | -17.1% | 71.5% | ||
| Q3 24 | -29.2% | 47.1% | ||
| Q2 24 | -18.9% | 46.7% | ||
| Q1 24 | -38.5% | 47.3% |
| Q4 25 | $-0.40 | $1.71 | ||
| Q3 25 | $1.67 | $1.74 | ||
| Q2 25 | $-0.33 | $1.61 | ||
| Q1 25 | $-0.74 | $1.56 | ||
| Q4 24 | $-0.30 | $1.85 | ||
| Q3 24 | $-0.46 | $1.60 | ||
| Q2 24 | $-0.30 | $1.56 | ||
| Q1 24 | $-0.54 | $1.56 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $5.5B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $3.3B |
| 总资产 | $1.1B | $16.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $5.5B | ||
| Q3 25 | $479.2M | $5.6B | ||
| Q2 25 | $370.0M | $5.8B | ||
| Q1 25 | $358.4M | $5.6B | ||
| Q4 24 | $411.3M | $5.4B | ||
| Q3 24 | $396.9M | $5.8B | ||
| Q2 24 | $360.1M | $5.7B | ||
| Q1 24 | $325.9M | $5.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $3.3B | ||
| Q3 25 | $401.2M | $3.1B | ||
| Q2 25 | $156.3M | $3.0B | ||
| Q1 25 | $164.2M | $2.9B | ||
| Q4 24 | $228.5M | $2.8B | ||
| Q3 24 | $237.1M | $2.7B | ||
| Q2 24 | $264.3M | $2.6B | ||
| Q1 24 | $266.7M | $2.5B |
| Q4 25 | $1.1B | $16.6B | ||
| Q3 25 | $1.1B | $16.6B | ||
| Q2 25 | $821.4M | $16.5B | ||
| Q1 25 | $807.3M | $16.3B | ||
| Q4 24 | $885.1M | $15.7B | ||
| Q3 24 | $901.9M | $15.9B | ||
| Q2 24 | $904.5M | $15.5B | ||
| Q1 24 | $831.9M | $15.4B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $491.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $472.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 217.2% |
| 资本支出强度资本支出/营收 | 0.1% | 8.3% |
| 现金转化率经营现金流/净利润 | — | 4.59× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $809.9M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $491.1M | ||
| Q3 25 | $108.5M | $115.2M | ||
| Q2 25 | $4.4M | $95.5M | ||
| Q1 25 | $-53.4M | $140.5M | ||
| Q4 24 | $19.4M | $473.9M | ||
| Q3 24 | $34.1M | $116.5M | ||
| Q2 24 | $-8.3M | $107.2M | ||
| Q1 24 | $-133.0M | $135.4M |
| Q4 25 | $-14.3M | $472.9M | ||
| Q3 25 | $108.3M | $112.2M | ||
| Q2 25 | $4.4M | $91.6M | ||
| Q1 25 | $-53.4M | $133.1M | ||
| Q4 24 | $19.3M | $459.8M | ||
| Q3 24 | — | $109.6M | ||
| Q2 24 | $-8.4M | $104.9M | ||
| Q1 24 | $-133.3M | $128.9M |
| Q4 25 | -7.1% | 217.2% | ||
| Q3 25 | 23.6% | 51.5% | ||
| Q2 25 | 2.5% | 44.0% | ||
| Q1 25 | -32.0% | 67.1% | ||
| Q4 24 | 9.1% | 220.8% | ||
| Q3 24 | — | 51.7% | ||
| Q2 24 | -4.2% | 50.5% | ||
| Q1 24 | -77.3% | 62.6% |
| Q4 25 | 0.1% | 8.3% | ||
| Q3 25 | 0.0% | 1.3% | ||
| Q2 25 | 0.0% | 1.9% | ||
| Q1 25 | 0.0% | 3.7% | ||
| Q4 24 | 0.0% | 6.8% | ||
| Q3 24 | 0.0% | 3.3% | ||
| Q2 24 | 0.0% | 1.1% | ||
| Q1 24 | 0.2% | 3.2% |
| Q4 25 | — | 4.59× | ||
| Q3 25 | 0.50× | 1.06× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | — | 1.45× | ||
| Q4 24 | — | 4.12× | ||
| Q3 24 | — | 1.17× | ||
| Q2 24 | — | 1.11× | ||
| Q1 24 | — | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
IBOC
暂无分部数据
